Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19
People’s long-term pain after knee surgery is reduced, new treatment has shown
27 January 2022How many times can I reuse my N95 mask?
28 January 2022Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19
A clinical trial has found that the combination of remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, is not more effective than remdesivir alone for treating adults hospitalized with the disease. The trial also found that the safety of this experimental treatment may vary depending on whether a person naturally generates SARS-CoV-2-neutralizing antibodies before receiving it. The results of the multinational Phase 3 trial were published today in the journal The Lancet.
